Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vigil Neuroscience, Inc. - Common Stock (NQ:VIGL)

8.050 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vigil Neuroscience, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Here are the top movers in Thursday's session.
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
On Friday, there are stocks with unusual volume. Let's take a look.
These stocks have an unusual volume in today's session 
Via Chartmill
Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3
Vigil Neuroscience's VG-3927 Phase 1 trial shows strong safety, 50% sTREM2 reduction, and potential Alzheimer's treatment; Phase 2 begins Q3 2025. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Upcoming Investor Conferences
From Vigil Neuroscience, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Cantor Global Healthcare Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Upcoming September Investor Conferences
From Vigil Neuroscience, Inc.
Via GlobeNewswire
VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q2 2024
VIGL stock results show that Vigil Neuroscience beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker
Vigil Neuroscience reports promising interim results from its Phase 1 trial of VG-3927, showing a strong safety, tolerability, and pharmacokinetic profile in healthy volunteers. The data support... 
Via Benzinga
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 33% Today?
Tonix Pharmaceuticals stock is falling on Thursday after the company announced a proposed public offering for shares of TNXP. 
Via InvestorPlace
Why Is Branchout Food (BOF) Stock Down 39% Today?
Branchout Food stock is down on Thursday after the company priced an offering of 1.75 million shares of BOF at 80 cents each. 
Via InvestorPlace
Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today?
Vigil Neuroscience stock is up with heavy trading of VIGL shares this morning on news of a $40 million investment from Sanofi. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning! 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.